On Tuesday, Shares of Fiat Chrysler Automobiles N.V. (NYSE:FCAU), lost -1.86% to $13.70.
Fiat Chrysler Automobiles declared that effective January 1, 2016, Richard Palmer is designated Chief Operating Officer Systems and Castings reporting directly to Chief Executive Officer Sergio Marchionne. Mr. Palmer will also retain his current responsibilities as FCA Chief Financial Officer and member of the Group Executive Council.
Mr. Palmer will succeed Riccardo Tarantini, who has elected to retire from the Group after more than 35 years of dedicated service. “We extend our sincere appreciation to Riccardo for his dedication, leadership and many contributions to the organization” said Sergio Marchionne.
Richard Palmer has served as Chief Financial Officer and member of the Group Executive Council (GEC) since September 1, 2011. He spent the early years of his career in Audit with Price Waterhouse Coopers and later with United Technologies Corp, and as Finance Manager for several business units at General Electric Oil & Gas. He joined FCA in 2003 in Comau and has since held various positions of increasing responsibility within the Group. Mr. Palmer is a Chartered Accountant and member of ICAEW (UK) and he holds a Bachelor of Science Degree in Microbiology from the University of Warwick (UK).
Fiat Chrysler Automobiles N.V., an automotive group, designs, engineers, manufactures, distributes, and sells vehicles and components. It offers passenger cars, light trucks, and light commercial vehicles under the Abarth, Alfa Romeo, Chrysler, Dodge, Fiat, Fiat Professional, Jeep, Lancia, and Ram brand names, in addition to after-sales services and parts under the Mopar brand name. The company also produces and sells luxury sport cars under the Ferrari and Maserati brands.
Shares of Century Aluminum Co. (NASDAQ:CENX), inclined 7.36% to $4.23, during its last trading session.
On Monday, shares in Century Aluminum Co. ended the session 3.14% higher at $3.94. The stock stated a trading volume of 1.68 million shares, below its three months average volume of 3.12 million shares. Shares of the company traded at a PE ratio of 9.85. Although, Century Aluminum Co.’s shares have advanced 8.84% in the last one month, it has declined 25.38% in the previous three months and 83.85% on YTD basis. The company is trading 4.75% below its 50-day moving average. Moreover, shares of Century Aluminum Co. have a Relative Strength Index (RSI) of 53.60.
Century Aluminum together with its auxiliaries produces primary aluminum in the United States and Iceland. It produces standard grade and value-added primary aluminum products; and carbon products, such as anodes and cathodes. The company was founded in 1995 and is headquartered in Chicago, Illinois.
Finally, Shares of Celgene Corporation (NASDAQ:CELG), ended its last trade with 0.27% gain, and closed at $111.14.
Celgene Corporation declared the settlement of litigation with Natco Pharma Ltd. of India, Natco’s U.S. partner, Arrow International Limited, and Arrow’s parent company, Watson Laboratories, Inc. (a wholly-owned partner of Allergan plc) regardingpatents for REVLIMID® (lenalidomide).
As part of the settlement, the parties will file Consent Judgments with the United States District Court for the District of New Jersey that enjoin Natco from marketing generic lenalidomide before the expiration of the patents-in-suit, except as offered for in the settlement, as described below.
In settlement of all outstanding claims in the litigation, Celgene will permit entry of generic lenalidomide before the April 2027 expiration of Celgene’s last-to-expire patent listed in the Orange Book for REVLIMID®. Celgene has agreed to provide Natco with a license to Celgene’s patents required to manufacture and sell an unlimited quantity of generic lenalidomide in the United States startning on January 31, 2026. In addition, Natco will receive a volume-limited license to sell generic lenalidomide in the United States commencing in March 2022. The volume limit is predictable to be a mid-single-digit percentage of the total lenalidomide capsules dispensed in the United States during the first full year of entry. The volume limitation is predictable to improvement gradually each 12 months until March of 2025, and is not predictable to exceed one-third of the total lenalidomide capsules dispensed in the U.S. in the final year of the volume-limited license under this agreement. Natco’s ability to market lenalidomide in the U.S. will be contingent on its obtaining approval of an Abbreviated New Drug Application.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID to treat multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, in addition to acute myeloid leukemia (AML).